» Articles » PMID: 3732318

Effect of Splenectomy on Destructive Bone Changes in Children with Chronic (Type I) Gaucher Disease

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 1986 Apr 1
PMID 3732318
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence and severity of osteolytic bone changes in patients with chronic (Type I) Gaucher disease splenectomized in the first decade of life were compared to those in patients of the same age group and similar degree of severity of the disease in whom the spleen remained intact at least until the second half of the second decade. The size of the spleen, measured by palpation, was used as an index of severity. In the splenectomized group osteolytic changes appeared within a few months following splenectomy in six out of eight cases. The changes were severe in five cases and moderate in one. In contrast, in the non-splenectomized group, evidence of bone destruction was found in two out of eight patients and classified as mild in both cases. Furthermore, in three patients in this group, who remained free of bone destruction until splenectomy in the second half of the second decade, osteolytic lesions appeared soon after the operation. Children with chronic Gaucher disease can be spared a great deal of suffering caused by bone disease, if splenectomy is avoided or postponed as far as possible.

Citing Articles

Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Tantawy A, Sherif E, Adly A, Hassanine S, Awad A J Inherit Metab Dis. 2013; 36(6):1025-37.

PMID: 23508695 DOI: 10.1007/s10545-013-9597-z.


Revised recommendations for the management of Gaucher disease in children.

Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M Eur J Pediatr. 2012; 172(4):447-58.

PMID: 22772880 DOI: 10.1007/s00431-012-1771-z.


Hyperferritinemia and iron overload in type 1 Gaucher disease.

Stein P, Yu H, Jain D, Mistry P Am J Hematol. 2010; 85(7):472-6.

PMID: 20575041 PMC: 2895498. DOI: 10.1002/ajh.21721.


Life expectancy in Gaucher disease type 1.

Weinreb N, Deegan P, Kacena K, Mistry P, Pastores G, Velentgas P Am J Hematol. 2008; 83(12):896-900.

PMID: 18980271 PMC: 3743399. DOI: 10.1002/ajh.21305.


Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Cox T, Aerts J, Belmatoug N, Cappellini M, Vom Dahl S, Goldblatt J J Inherit Metab Dis. 2008; 31(3):319-36.

PMID: 18509745 DOI: 10.1007/s10545-008-0779-z.


References
1.
Brady R, Kanfer J, Shapiro D . METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. Biochem Biophys Res Commun. 1965; 18:221-5. DOI: 10.1016/0006-291x(65)90743-6. View

2.
MATOTH Y, Fried K . Chronic Gaucher's disease; clinical observations on 34 patients. Isr J Med Sci. 1965; 1(4):521-30. View

3.
SILVERSTEIN M, Kelly P . Osteoarticular manifestations of Gaucher's disease. Am J Med Sci. 1967; 253(5):569-77. View

4.
Dreborg S, Erikson A, Hagberg B . Gaucher disease--Norrbottnian type. I. General clinical description. Eur J Pediatr. 1980; 133(2):107-18. DOI: 10.1007/BF00441578. View